It is always time to test: Spring European Testing Week
In order to maximise the benefits of treatment for HIV or viral hepatitis, it is critical to test and diagnose people as soon as possible in the course of the infection. ECDC supports this objective of European Testing Week.
Health risks during the Carnival season in Brazil
The Carnival season will last from 1 to 9 March 2019. In Rio de Janeiro, Brazil, 1 million participants are expected, including many travellers from Europe
Surveillance systems overview for 2017
- Chikungunya virus disease
- Chlamydia infection
- Crimean-Congo haemorrhagic fever
- Ebola haemorrhagic fever
- Hantavirus infection
- Healthcare-associated infections
- Hepatitis A
- Hepatitis B
- Hepatitis C
- HIV infection
- Invasive Haemophilus influenzae disease
- Lassa fever
- Marburg haemorrhagic fever
- Meningococcal disease
- Pneumococcal disease
- Q fever
- Rift Valley fever
- Severe acute respiratory syndrome (SARS)
- Surgical site infections
- Verotoxigenic Escherichia coli infection
- West Nile virus infection
- Yellow fever
Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA
The ECDC guidance on integrated testing of hepatitis B (HBV), hepatitis C (HCV) and HIV supports countries in the global effort to combat viral hepatitis and eliminate HIV as public health threats by 2030. At present, reaching and testing those at risk of infection with HIV, HBV or HCV is still a public health challenge across Europe. This Guidance in brief is based on the comprehensive guidance document which provides the evidence base for this guidance
Public health guidance on HIV, hepatitis B and C testing in the EU/EEA
This guidance aims to provide EU/EEA countries with an evidence-based framework to help develop, implement, monitor and evaluate their own national HBV, HCV and HIV testing guidelines and programmes.
Marking European Testing Week: ECDC issues integrated hepatitis and HIV testing Guidance
To mark European Testing Week from 23 to 30 November 2018, ECDC publishes its new Guidance on integrated viral hepatitis and HIV testing.
Public health guidance on prevention and control of blood-borne viruses in prison settings
This document provides EU/EEA Member States with evidence-based scientific advice on available options, when planning and implementing prevention and control interventions for blood-borne viruses in prison settings.
Preventing blood-borne viruses in prison settings: ECDC and EMCDDA Guidance
People in prison experience a higher burden of communicable diseases such as hepatitis B (HBV), hepatitis C (HCV) and HIV often linked to a history of injecting drug use.
Guidance in brief: Prevention and control of blood-borne viruses in prison settings
This guidance is intended for policymakers responsible for the planning and delivery of healthcare services in the national or sub-national custodial system and all professionals responsible for the health and well-being of people in prison, including community-based service providers and those facilitating continuity of care in the community.
Systematic review on the prevention and control of blood-borne viruses in prison settings
The objective of this report was to systematically review data on prevention and control of BBVs in prison settings, with a focus on the countries of the European Union (EU) and the European Economic Area (EEA).